Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

Chatphatai Moonla, MD, MSc1,2, Darintr Sosothikul, MD3,4, Thita Chiasakul, MD, MSc1,2, Ponlapat Rojnuckarin, MD, PhD1,2, and Noppacharn Uaprasert, MD1,2

Abstract

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease severity during hospitalization but the reported survival benefits from anticoagulation (AC) vary among studies. We performed a literature research to estimate pooled odds ratios (ORs) of in-hospital mortality and major bleeding comparing among intermediate-to-therapeutic dose AC, prophylactic dose AC, and no AC. Until October 22, 2020, PubMed, EMBASE, and Cochrane Library Database were searched for studies reporting AC utilization and mortality in COVID-19. Studies with suspected risk of bias were excluded before the synthesis of pooled ORs with 95% confidence intervals (CIs) using random-effects models. Of 37 identified studies (N = 19,510), 17 (N = 17,833) were aggregated in the meta-analysis. The overall mortality rate was 23.1% (95% CI 18.7-28.2). The pooled odds of mortality comparing anticoagulated to non-anticoagulated patients were similar, but lower in prophylactic dose AC group (OR 0.83; 95% CI 0.73-0.95). Notably, intermediate-to-therapeutic dose AC increased mortality (OR 1.60; 95% CI 1.11-2.31) and major bleeding compared to prophylactic dose AC (OR 3.33; 95% CI 2.34-4.72). Our findings support the optimal efficacy and safety profiles of prophylactic dose AC in hospitalized COVID-19 patients.

Keywords

COVID-19, SARS-CoV-2, anticoagulation, mortality, meta-analysis

Introduction

By the end of January 2021, the global spread of coronavirus diseases 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected more than 100 million people worldwide with approximately 2-3% case fatality, which could be up to 15-27% in hospitalized patients.1 Although SARS-CoV-2 primarily infects respiratory organs, significant numbers of patients encounter systemic complications associated with proinflammatory cytokine overproduction, endotheliopathy, hypercoagulability, and thromboembolism.2-5 Supported by the high prevalence of elevated plasma D-dimer levels6 and postmortem findings of alveolar capillary microthrombi among critical cases,2,7 activation of pulmonary intravascular coagulation may play an important role in the pathophysiology of severe COVID-19 pneumonia and acute respiratory distress syndrome. Moreover, emerging studies reveal the apparently high prevalence of arterial and...
venous thromboembolisms among hospitalized COVID-19 population, 18-28% in the intensive care unit (ICU) and 5-11% in non-ICU circumstances.\(^9\) Notably, the thrombosis is associated with the higher mortality (pooled odds ratio [OR] 1.74; 95% confidence interval [CI] 1.01-2.98).\(^9\) Anticoagulation (AC) therapy has been proposed to counteract the underlying prothrombotic mechanisms. Although several randomized controlled trials (RCTs) are ongoing,\(^10\) the expert consensus recommends AC in all hospitalized COVID-19 patients in the absence of absolute contraindications,\(^11,12\) primarily aiming for thromboprophylaxis.

The rationale behind AC is not only derived from evidence-based recommendations on thromboprophylaxis for hospitalized medical illness,\(^13\) but also from a few cohort studies observing impact of AC on COVID-19 mortality. The first retrospective study from China\(^14\) reported the association between prophylactic dose AC, using low molecular weight heparin (LMWH) or unfractionated heparin (UFH), and better survival of patients with severe COVID-19 pneumonia in a subgroup of markedly coagulopathy defined by high D-dimer levels and sepsis-induced coagulopathy score. A subsequent larger United States cohort\(^15\) demonstrated lower mortality in COVID-19 subjects who received any doses of AC, compared to those without AC. Because thromboembolic rates are still high in COVID-19 patients despite prophylactic dose AC,\(^16\) higher doses of AC are increasingly prescribed. Nevertheless, in-hospital mortality rates of prophylactic dose and therapeutic dose AC groups were not significantly different, while therapeutic dose AC possibly increased bleeding complications.\(^15,17\) Therefore, the role of high-intensity AC in COVID-19 remains controversial.\(^12\)

Consequently, we conducted a systematic review and meta-analysis of published data to estimate the associations between the AC utilization/intensity and mortality, as well as bleeding rates, of COVID-19 patients during hospitalization.

**Methods**

The protocol for this literature research was prespecified before study initiation. Relevant randomized and non-randomized studies were systematically analyzed, and extractable data were analyzed, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.\(^18\) The primary aim of this research was to evaluate the impact of AC, either prophylactic or intermediate-to-therapeutic doses, on mortality of hospitalized patients with COVID-19. The effects of different AC dosages on major bleeding complication were determined as the secondary objectives.

**Eligibility Criteria**

Research articles published between the inception of COVID-19 and October 22, 2020 in any formats (i.e. full-length original articles, brief reports, letters, or conference abstracts) and languages, were eligible for inclusion into the systematic review. The inclusion criteria consisted of the studies reporting mortality and the AC uses among adult patients (age ≥18 years) hospitalized due to objectively confirmed COVID-19. Prospective or retrospective observational studies and RCTs recruiting at least 10 participants were included. Non-original studies (i.e. reviews, commentaries, guidelines, or trial protocols), duplicated studies, and studies with inappropriate designs for estimating mortality from COVID-19 (i.e. autopsy studies, case reports or case series which exclusively enrolled patients with trauma, surgeries, or thrombotic complications) were excluded. Finally, only studies which adequately described mortality based upon the AC utilization and dose intensities were qualified for statistical estimations in the comparative meta-analysis.

**Literature Search Strategy**

A systematic search was performed on 3 online databases including PubMed, EMBASE, and Cochrane Library Database. A manual search of relevant journals and eligible abstracts from the international conferences was supplementally conducted. The search terms used on the electronic databases were the combination of the following words: anticoagulation, anticoagulant, anticoagulated, mortality, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, novel coronavirus 2019, 2019-nCoV, coronavirus disease 2019, and COVID-19. The PRISMA flowchart illustrates the results of the literature search and study selection (Figure 1).

**Data Extraction and Data Synthesis**

Included studies were reviewed for data extraction. If different studies reported the results from the same cohort or trial population, only the study with more maturity of data would be quantitatively appraised. Prespecified independent and dependent variables were extracted from each study as follows: study design, number of total study participants, number of patients with critical illness,\(^19\) invasive mechanical ventilators or requiring ICU hospitalization, baseline characteristics (mean age, gender, comorbidities, and laboratory profiles), adjuvant treatments for COVID-19,\(^20\) administration of AC, and outcomes of interest (in-hospital death and major bleeding).

In this review, prophylactic dose AC\(^13\) was defined as subcutaneous enoxaparin 40-60 mg or 0.5-1.0 mg/kg once daily, subcutaneous nadroparin 2,850-5,700 IU once daily, subcutaneous UFH 5,000 U every 8-12 hours, subcutaneous
fondaparinux 2.5 mg once daily, or oral apixaban 2.5 mg twice daily. Intravenous UFH, oral vitamin K antagonists targeting therapeutic international normalized ratio, or any AC doses higher than the prophylactic levels were categorized as intermediate-to-therapeutic dose AC. If these details of AC administration were not described, the AC doses would be defined according to the authors in each study.

The primary outcome of the meta-analysis was in-hospital mortality, which was referred to deaths from any causes during hospitalization due to COVID-19. Major bleeding adverse events (AEs) following the International Society on Thrombosis and Haemostasis (ISTH) criteria for non-surgical patients were the secondary outcome. For the primary analysis, mortality outcomes were stratified based upon the AC uses (AC versus no AC) and subsequently by the AC intensities (prophylactic versus intermediate-to-therapeutic dose AC). Two authors (C.M. and D.S.) separately performed data extraction from eligible studies. The consensus with the third author (P.R.) was necessary in a discordance.

**Quality Assessment**

Methodological quality of eligible studies was evaluated independently by 2 authors (C.M. and D.S.) using validated tools for assessing risk of bias: the Newcastle-Ottawa Scale (NOS) for cohort studies, and the modified Cochrane Collaboration tool for RCTs. The NOS assigns 0-9 points according to 3 quality domains: selection, comparability, and outcome. Total NOS scores <5 points, 0-1 point in the selection, 0 point in the comparability, or 0-1 point in the outcome domains define a study with low quality or at potential risk of bias. The Cochrane risk-of-bias tool comprises 7 items from 6 bias domains. Overall risk of bias based upon the summary of responses to all
7 items categorizes a RCT into low, high, or unclear risks of bias. Scoring discrepancies were resolved by a joint re-assessment of the article (C.M., D.S., and P.R.).

Statistical Methods

Statistical operations were performed using Comprehensive Meta-Analysis version 3.0 (Biostat Inc., Englewood, NJ, USA). Using the DerSimonian and Laird method with random-effects models, we calculated the pooled event rates and risk estimates (pooled ORs and 95% CIs) for in-hospital mortality by the AC uses and intensities. The prespecified subgroup analyses comparing no AC to prophylactic dose or intermediate-to-therapeutic dose AC were subsequently conducted. The pooled event rates and ORs for major bleeding AEs by the AC intensities were estimated in the secondary analysis. Results from the studies with zero outcome event, the studies with low methodological quality, or the studies at high risk of bias were not aggregated in the comparative meta-analysis. Continuous variables reported as medians with interquartile ranges were converted to estimated means with standard deviations before quantitative synthesis into the pooled means and 95% CIs within random-effects models.

Between-study heterogeneity was measured by the I² statistic. The I² of 0-25%, 26-50%, 51-75%, and >75%, indicated insignificant, low, moderate, and high heterogeneity, respectively. When at least 10 studies were aggregated in the meta-analysis, potential publication bias was assessed by visual inspection of the funnel plots and statistical estimation by the Egger’s regression test.

Results

From 363 studies identified by the literature search, titles and abstracts of 292 unique studies which fulfilled the inclusion criteria were screened for eligibility. Since 201 studies were excluded according to at least 1 criterion of exclusion, 91 studies remained for the full-text evaluation. Of those, 37 criteria were screened for eligibility. Since 201 studies were conducted in Europe, the largest fraction of participants (66.1%) belonged to 11 studies from North America.

Between-study heterogeneity was measured by the I² statistic. The I² of 0-25%, 26-50%, 51-75%, and >75%, indicated insignificant, low, moderate, and high heterogeneity, respectively. When at least 10 studies were aggregated in the meta-analysis, potential publication bias was assessed by visual inspection of the funnel plots and statistical estimation by the Egger’s regression test.

Among the included studies, anticoagulants were prescribed in 80.3% of hospitalized patients with COVID-19. More than half of those received prophylactic dose AC. Among 3,840 patients who were not exposed to AC during their hospital courses, 1,086 cases (28.3%) came from 4 studies in Asian population. Compared with the studies from the other continents, the Asian studies reported substantially lower rates of the AC utilization (25.8% versus 82.7% in the North American and 89.8% in the European populations).

Collective data on clinical characteristics of 19,510 patients are presented in Table 2. The weighted mean of participant age was 61.7 years (95% CI 60.1-63.3) and 42.4% of overall population were female. Hypertension and diabetes mellitus were common comorbidities. Despite limited data on COVID-19 specific treatments, the administrations of hydroxychloroquine and systemic corticosteroids were implemented in 79.9% and 47.0% of patients, respectively. Pooled analyses of the potential coagulation parameters revealed the elevation of D-dimer and fibrinogen levels confirming the findings from the previous meta-analysis. Based on the AC uses, patients who received AC had a higher proportion of ICU admission or critical illness (54.3% versus 17.7% in no AC group). Main characteristics of each included study are described in the supplementary Table S1.

Table 1. Methodological Characteristics of 37 Studies Included in the Systematic Review.

| Characteristics                                      | No. of studies | No. of participants |
|------------------------------------------------------|----------------|---------------------|
| Study design                                         |                |                     |
| Randomized controlled trial                          | 1              | 20                  |
| Prospective cohort                                   | 11             | 1,964               |
| Retrospective cohort                                 | 25             | 17,526              |
| Single-center study                                  | 24             | 5,328               |
| Multi-center study                                   | 13             | 14,182              |
| Geographical location                                |                |                     |
| Asia                                                 | 4              | 1,464               |
| Europe                                               | 21             | 5,121               |
| North America                                        | 11             | 12,905              |
| South America                                        | 1              | 20                  |
| Hospitalization or disease severity setting          |                |                     |
| ICU/critically ill                                   | 34             | 6,118               |
| Non-ICU/non-critically ill                           | 17             | 10,434              |
| Unstratified hospitalization setting                 | 2              | 2,958               |
| AC utilization                                       |                |                     |
| No AC                                                | 37             | 3,840               |
| Prophylactic dose AC                                 | 33             | 9,748               |
| Intermediate-to-therapeutic dose AC                  | 33             | 3,886               |
| Undefined doses of AC                                | 4              | 2,036               |
| Reported mortality outcome                           |                |                     |
| No AC                                                | 15             | 3,648               |
| Prophylactic dose AC                                 | 20             | 9,109               |
| Intermediate-to-therapeutic dose AC                  | 20             | 3,657               |
| Any AC                                               | 36             | 15,484              |

Abbreviations: AC, anticoagulation; ICU, intensive care unit.
**Table 2. Patient Characteristics From 37 Studies Included in the Systematic Review.**

| Characteristics                      | No. of studies | No./total of participants (%) or estimated values |
|---------------------------------------|----------------|--------------------------------------------------|
| Mean age (years, 95% CI)              | 37             | 61.7 (60.1-63.3)                                 |
| Gender                                |                |                                                  |
| Female                                | 37             | 8,280/19,510 (42.4)                              |
| Male                                  | 37             | 11,230/19,510 (57.6)                              |
| No. of ICU or critically ill patients |                |                                                  |
| No AC                                 | 7              | 186/1,053 (17.7)                                 |
| AC                                    | 25             | 5,106/9,403 (54.3)                               |
| Prophylactic dose AC                  | 20             | 3,682/7,098 (51.9)                               |
| Intermediate-to-therapeutic dose AC    | 18             | 1,335/2,216 (60.2)                               |
| Overall population                    | 34             | 6,118/16,228 (37.7)                              |
| Comorbidities                         |                |                                                  |
| Hypertension                          | 21             | 6,821/14,485 (47.1)                              |
| Diabetes mellitus                     | 22             | 4,313/14,774 (29.2)                              |
| Cardiovascular disease                | 16             | 893/12,343 (7.2)                                 |
| Ischemic heart disease                | 11             | 1,622/12,829 (12.6)                              |
| Congestive heart failure              | 5              | 845/10,817 (7.8)                                 |
| Cerebrovascular disease               | 4              | 392/4,510 (8.7)                                  |
| Chronic pulmonary disease             | 16             | 1,856/11,404 (16.3)                              |
| Chronic liver disease                 | 3              | 84/4,933 (1.7)                                   |
| Chronic kidney disease                | 10             | 815/9,607 (8.5)                                  |
| Malignancy                            | 15             | 852/12,479 (6.8)                                 |
| Current- or ex-smoker                 | 13             | 1,721/11,962 (14.4)                              |
| Obesity                               | 13             | 1,434/7,900 (18.2)                               |
| Prior VTE                             | 13             | 255/4,428 (5.8)                                  |
| Immunocompromised status              | 4              | 79/4,603 (1.7)                                   |
| COVID-19 adjuvant treatments          |                |                                                  |
| Remdesivir                            | 5              | 40/562 (7.1)                                     |
| Convalescent plasma                   | 2              | 29/205 (14.1)                                    |
| Interleukin-6 receptor inhibitors a   | 7              | 551/2,997 (18.4)                                 |
| Corticosteroids                       | 9              | 3,137/6,861 (47.0)                               |
| Hydroxychloroquine                    | 9              | 5,223/6,541 (79.9)                               |
| Selected laboratory parameters        |                |                                                  |
| Mean platelets (x 10^10 cells/µL, 95% CI) | 26 | 230.1 (218.8-241.5)                             |
| Mean D-dimer (µg/mL, 95% CI)          | 30             | 2.32 (1.99-2.65)                                 |
| Mean fibrinogen (g/L, 95% CI)         | 18             | 6.25 (5.25-7.25)                                 |
| Crude in-hospital mortality rates     |                |                                                  |
| No AC                                 | 15             | 772/3,648 (21.2)                                 |
| AC                                    | 36             | 3,669/15,484 (23.7)                              |
| Prophylactic dose AC                  | 20             | 2,076/9,109 (22.8)                               |
| Intermediate-to-therapeutic dose AC    | 20             | 1,148/3,657 (31.4)                               |
| Overall population                    | 37             | 4,506/19,510 (23.1)                              |

Abbreviations: AC, anticoagulation; CI, confidence interval; COVID-19, coronavirus disease 2019; VTE, venous thromboembolism.

aReported uses of interleukin-6 receptor inhibitors included tocilizumab and sarilumab.

**Risk of Bias**

The quality assessment of 37 eligible studies was aimed to evaluate the potential risk of bias related to the exposure to AC and the reported mortality. Apart from appraising the generalizability of exposure and outcomes of interest, our evaluations were not judgment of the general quality or scientific merits of the included studies. The details on methodological assessment of 36 cohort studies and 1 RCT are presented in the supplementary Table S2 and Table S3, respectively. Eighteen studies were excluded from the meta-analysis due to their high risk of bias: 17 studies for limitations on comparability, and 8 studies for outcome assessment. Two studies, 43, 48 albeit qualified by the NOS, were subsequently excluded due to the lack of stratification of mortality by the AC doses. Hence, 17 studies remained at the final for the comparative meta-analysis.

In the primary and the secondary analyses, 2 meta-analysis models comprising the results of at least 10 studies were evaluated for the publication bias. Although the funnel plot from 1 out of 2 evaluable models was asymmetrical, the Egger’s regression intercept did not indicate a significant risk of publication bias. The funnel plots of both meta-analysis models are illustrated in the supplementary Figure S1.

**Anticoagulation and In-Hospital Mortality**

After methodological assessment, data from 17 qualified studies involving 17,833 hospitalized patients were analyzed. Clinical characteristics of the study subjects aggregated in the meta-analysis are summarized in the supplementary Table S4. The mean age of participants was 63.7 years (95% CI 62.3-65.1). Less than a half of patients were female (42.7%) and treated in ICU setting (33.9%). The pooled rates of in-hospital mortality of all, non-anticoagulated, and anticoagulated patients were 23.1% (95% CI 18.7-28.2; I^2 = 98%), 21.4% (95% CI 16.3-27.7; I^2 = 92%), and 24.3% (95% CI 19.5-29.8; I^2 = 98%), respectively. For the primary analysis, the quantitative results from 10 studies (58.8%) reporting the number of patients with no AC, were pooled to determine the odds of in-hospital mortality comparing anticoagulated to no AC group. Among 13,124 patients (1,911 critically ill, 9,105 non-critically ill, and 2,108 unclassified cases), the AC use was not associated with the lower in-hospital mortality from COVID-19 (OR 1.19; 95% CI 0.90-1.58; I^2 = 74%; Figure 2A). However, in the prespecified analyses of subpopulations stratified by the AC intensities, the pooled odds of mortality were 17% lower in patients receiving prophylactic dose AC (OR 0.83; 95% CI 0.73-0.95; P = 0.006; I^2 = 0%; Figure 2B), but 64% higher among the patients receiving intermediate-to-therapeutic dose AC, when compared to those with no AC (OR 1.64; 95% CI 1.15-2.35; P = 0.007; I^2 = 68%; Figure 2C). A post hoc analysis in ICU/critically ill subgroup could not be performed due to the limited report on outcome stratified by COVID-19 severity.

Concerning the different rates of in-hospital thromboprophylaxis between Asian and Western studies, post hoc analyses stratified by the study continents revealed the similar pooled effects of AC as in the prespecified analyses. Nevertheless, the survival benefit of prophylactic dose AC compared to no AC was significant solely in the Western subgroup (OR 0.82; 95% CI 0.69-0.99; P = 0.035; I^2 = 22%) but not in the Asian subgroup (OR 0.93; 95% CI 0.60-1.45; I^2 = 0%; the supplementary Figure S2). The impact of intermediate-to-therapeutic dose AC was significant solely in the Western subgroup (OR 0.82; 95% CI 0.69-0.99; P = 0.035; I^2 = 22%).
Figure 2. Pooled odds of mortality among hospitalized COVID-19 patients with anticoagulation compared to patients without anticoagulation: (A) any anticoagulation, (B) prophylactic dose anticoagulation, and (C) intermediate-to-therapeutic dose anticoagulation. Abbreviation: df, degree of freedom.
AC in the Asian population was undetermined since none of them specified AC doses higher than the prophylactic levels.

**Intermediate-to-Therapeutic Versus Prophylactic Dose Anticoagulation and In-Hospital Mortality**

Eleven studies (64.7%) reporting fatality in 3,385 patients who received intermediate-to-therapeutic dose (27.8%; 95% CI 21.5-35.2; I² = 93%) and 8,639 patients who received prophylactic dose AC (20.4%; 95% CI 14.3-28.2; I² = 98%) were aggregated in the secondary analysis. In a total of 12,024 cases, COVID-19 patients with intermediate-to-therapeutic dose AC had 60% significantly higher odds of mortality compared to those with prophylactic dose AC (OR 1.60; 95% CI 1.11-2.31; P = 0.012; I² = 89%; Figure 3).

In a sensitivity analysis by removing a study with a unique protocol of AC titration using an individual risk of thrombosis,56 the survival benefit of prophylactic dose AC was still present (OR 1.42; 95% CI 1.05-1.93; P = 0.022; I² = 81%). Moreover, a post hoc analysis integrating multiple subgroups of the disease severities demonstrated the reproducibility of those pooled risk estimates (OR 1.50; 95% CI 1.07-2.11; P = 0.018; I² = 89%). Including 4 studies which solely enrolled 2,996 critically ill patients, the higher AC intensity was not related to the greater risk of deaths during ICU hospitalization (OR 1.08; 95% CI 0.60-1.95; I² = 41%; the supplementary Figure S3).

**Anticoagulation and Major Bleeding Complications**

For the secondary outcome, major bleeding AEs were documented clearly in 9 studies (52.9%) covering 10,609 hospitalized patients (2,560 patients with intermediate-to-therapeutic dose AC, 5,835 with prophylactic dose AC, and 2,214 with no AC). The pooled event rates of major bleeding among all patients, patients with no AC, prophylactic dose AC, and intermediate-to-therapeutic dose AC were 4.8% (95% CI 3.0-7.6; I² = 94%), 3.5% (95% CI 1.9-6.6; I² = 75%), 2.6% (95% CI 1.7-4.1; I² = 78%), and 9.6% (95% CI 5.8-15.6; I² = 89%), respectively.

The quantifiable results from 8 out of 9 studies reporting bleeding complications in both dose levels of AC were analyzed. The pooled odds of major bleeding were approximately 3 folds greater in intermediate-to-therapeutic dose compared to prophylactic dose AC groups (OR 3.34; 95% CI 2.22-5.04; P < 0.001; I² = 30%; Figure 4). These effects were comparable to the pooled risk estimates from a post hoc analysis comprising all subgroups of COVID-19 severities (OR 3.34; 95% CI 2.22-5.04; P < 0.001; I² = 30%) or solely ICU subpopulation (OR 3.58; 95% CI 1.49-8.62; P = 0.004; I² = 0%; the supplementary Figure S4).

Furthermore, the odds of major bleeding comparing any doses of AC to no AC were collated using the quantitative data of 9,674 participants from 5 studies. Administration of intermediate-to-therapeutic dose AC increased the pooled odds of major bleeding (OR 2.11; 95% CI 1.18-3.76; P = 0.011; I² = 56%). However, prophylactic dose AC was not significantly associated with an increase in major bleeding compared to no AC (OR 0.52; 95% CI 0.25-1.05; I² = 59%; the supplementary Figure S5).

**Discussion**

In this systematic review, we gathered data from 37 studies describing pharmacological thromboprophylaxis and mortality in 19,510 SARS-CoV-2-infected patients during
hospitalization. Considering data of 17,833 participants from 16 observational studies and 1 RCT aggregated in the comparative meta-analysis, the in-hospital mortality rates were substantially high regardless of the AC uses and intensities (27.8% in intermediate-to-therapeutic dose AC, 20.4% in prophylactic dose AC, and 21.4% in no AC groups). The mortality of anticoagulated versus non-anticoagulated patients were not different.

Comparing to no AC group, prophylactic dose AC significantly decreased the odds of in-hospital death by 17%, despite a lower proportion of critically ill patients in no AC group. This may suggest a beneficial role of prophylactic dose AC as part of COVID-19 treatment. On contrary, intermediate-to-therapeutic dose AC was associated with the higher odds of mortality. A possible explanation for this adverse outcome was a large proportion of critically ill patients in intermediate-to-therapeutic dose AC group (60.2% versus 17.7% in no AC and 51.9% in prophylactic dose AC groups). Consistently, an ICU subgroup analysis showed similar odds of mortality among critically ill patients with intermediate-to-therapeutic dose AC and those with prophylactic dose AC.

A proposed mechanism for AC benefit in COVID-19 treatment is to suppress prothrombotic coagulopathy preventing thrombosis in micro- and macro-vasculatures. \(^{61}\) Furthermore, several inflammatory markers, i.e. C-reactive protein (CRP), erythrocyte sedimentation rate, procalcitonin, and ferritin, are elevated in COVID-19 patients and correlated with thrombotic complications. \(^{62}\) Therefore, anti-inflammatory effects of LMWH and UFH \(^{63,64}\) including neutralization of cytokines, chemokines, and extracellular histones may be advantageous for COVID-19 patients beyond their anticoagulant properties. Laboratory profiles of the study participants in this meta-analysis (the supplementary Table S4) showing the increases in D-dimer, fibrinogen, CRP, and procalcitonin potentially support this hypothesis. Moreover, LMWH and UFH can also reduce SARS-CoV-2 cellular entry by competitively binding to heparan sulfate on host cell membrane. \(^{63,64}\) While prophylactic dose AC does not reduce in-hospital mortality of patients with acute medical illnesses other than COVID-19, \(^{13,65}\) the current evidence suggests a unique pathogenesis of SARS-CoV-2 infection that can be alleviated by an appropriate dose of AC and also support the guidelines recommending prophylactic dose AC in both critically ill and non-critically ill hospitalized COVID-19 patients.

A recent systematic review and meta-analysis of 35 studies disclosed that hospitalized COVID-19 patients who received AC developed substantially lower thrombotic rates (10.5-19.8% venous and 1.3-2.5% arterial thrombosis) compared to those without AC (41.9% venous and 11.3% arterial thrombosis), although thrombotic rates in prophylactic dose and high-intensity AC groups were not significantly different. \(^{17}\) A post hoc quantitative synthesis of available data from 4 studies \(^{40,44,45,51}\) involving 811 patients in this meta-analysis also revealed similar odds of venous thrombosis when comparing intermediate-to-therapeutic dose to prophylactic dose AC groups (OR 1.98; 95% CI 0.99-3.93; \(I^2 = 0\%\)). Within this frame of evidence, increased intensity of AC may be ineffective, not only in reducing thrombosis, but also in improving survival. Targeting systemic hyperinflammation in SARS-CoV-2 infection by immunomodulatory methods \(^{20,66,67}\) should be considered rather than escalating dose of AC.

Cardiovascular comorbidities are associated with high fatality rates of COVID-19 patients. \(^{19}\) In the presence of systemic hyperinflammation and endotheliopathy due to COVID-19, coronary microvascular dysfunction and destabilized atherosclerotic plaques may aggravate underlying cardiac conditions and possibly lead to deaths. \(^{68,69}\) In this meta-analysis, 18.4% of COVID-19 patients who received intermediate-to-therapeutic dose AC had ischemic heart disease, higher than those who received prophylactic dose AC (11.4%) and those who did not (10.8%; the supplementary Table S4). This factor may partially
Contribute to the higher mortality rates among high-intensity AC group. Consequently, cardiologists should be involved early in the multidisciplinary management team for COVID-19 patients with preexisting cardiovascular diseases. 69 Coagulopathy in COVID-19 is not only related to thrombotic but also to bleeding complications, particularly in the presence of overt disseminated intravascular coagulation, thrombocytopenia, or hypofibrinogenemia. 62 Although the elevated D-dimer levels and the prolonged clotting times were commonly observed in this meta-analysis (the supplementary Table S4), prophylactic dose AC did not increase major bleeding rates compared to no AC and yielded significantly lower rates than that of intermediate-to-therapeutic dose AC (2.6% versus 9.6%). This harmful effect, therefore, did not support the use of high-intensity AC. Moreover, exposure to LMWH or UFH possibly cause heparin-induced thrombocytopenia (HIT) which may lead to thrombosis via platelet-activating antiplatelet factor 4/heparin antibodies. 70, 71 Recent retrospective studies 72, 73 highlighted the burden of HIT among hospitalized COVID-19 patients who received LMWH or UFH as thromboprophylaxis. The impact of heparin dosages on HIT development is uncertain as data are lacking. One study 42 in our meta-analysis described HIT in only 0.05% of patients who received prophylactic dose AC (1/2,121) but 1.1% of patients who received increased intensity of AC (11/998). Exploring the HIT incidence in a larger COVID-19 population is warranted.

Two recently published systematic reviews 74, 75 reported the uses of AC to improve survival of hospitalized COVID-19 patients. One review with a subsequent meta-analysis 74 concluded that any AC and intermediate-to-therapeutic dose AC were associated with the lower COVID-19 mortality based upon data from 6 observational studies. However, the other review 75 revealed conflicting effects of therapeutic dose AC on COVID-19 mortality based upon data from 8 observational studies. Our updated literature research accumulated more mature data from 17 studies in the meta-analysis, including several large cohorts and 1 RCT. We confirmed the survival benefit from prophylactic dose AC in hospitalized COVID-19 patients, but with the negative impact of high-intensity AC. Additionally, we conducted the pooled analysis on major bleeding which was undetermined in the prior reviews. This meta-analysis presents both efficacy and safety outcomes of AC that would be helpful for a clinical decision on COVID-19 management.

Study Limitations
The majority of included studies in this systematic review are retrospective or prospective cohorts that assign mortality as the secondary outcome. The meta-analysis assembling data from observational studies undeniably contain limitations, i.e. among-study heterogeneity, selection bias, and various confounders. 76 First, there may be a tendency to prescribe intermediate-to-therapeutic dose AC to more severe patients. Imbalance of baseline characteristics among comparative arms of interventions could limit an interpretation of their effects on outcomes. In this context, we tried to perform post hoc analyses in the ICU/critically ill subgroup when data were available. Second, the reported data on other adjunctive treatments for COVID-19 were limited. Third, subtherapeutic doses of AC used in the included studies were highly variable. Therefore, we combined any increased intensity of AC into intermediate-to-therapeutic dose AC group to ease the quantitative synthesis. Fourth, although direct oral anticoagulants (DOACs), i.e. apixaban 2.5 mg twice daily, 77 rivaroxaban 10 mg once daily, 78 and betrixaban 80 mg once daily, 79 may be used as pharmacological thromboprophylaxis in acutely ill medical patients, studies using prophylactic doses of DOACs other than apixaban 15, 40 in COVID-19 population are lacking. Fifth, due to the limited number of the Asian studies, prophylactic dose AC did not significantly reduce the in-hospital mortality from COVID-19 compared to no AC in this subgroup (the supplementary Figure S2). The AC effects in various ethnic groups deserve further investigations. 80 Ongoing RCTs 10 which directly compare effectiveness of prophylactic dose to higher doses of AC in COVID-19 will provide stronger evidence for clinical practice.

Conclusions
We discovered that the standard prophylactic dose of AC was associated with lower in-hospital mortality from COVID-19 without excess bleeding. On contrary, the intermediate-to-therapeutic dose AC revealed no survival benefit but a 3-fold increase in major bleeding. Results from upcoming RCTs are required to confirm our findings.

Acknowledgments
We are much obliged to Associate Professor Paweena Susantitaphong, MD, PhD, Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, for her dedicated assistance and guidance on the meta-analysis methodology. We also would like to thank Associate Professor Wanla Kulwichit, MD, Information Technology Center, and Research Affairs, Faculty of Medicine, Chulalongkorn University, as well as Assistant Professor Udomsak Bunvorasate, MD, our research unit director, for the great support on this manuscript during the difficult times of COVID-19 era.

Author Contributions
CM contributed to study design, data collection, data interpretation, statistical analysis, and writing the first draft of manuscript; DS contributed to study design, data collection, and data interpretation; TC and NU contributed to study design and critical review of the manuscript; PR contributed to study design, data interpretation, and critical review of the manuscript; all authors contributed to revision of the final manuscript.

Ethics Approval
Our institution did not require ethical approval or informed consent from the patient(s) for reporting a systematic review and meta-analysis.
Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Chatphatai Moonla https://orcid.org/0000-0001-6257-0867
Ponlapat Rojnuckarin https://orcid.org/0000-0001-7912-1996
Noppacharn Uaprasert https://orcid.org/0000-0003-4562-9139

Supplemental Material

Supplemental material for this article is available online.

References

1. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. J Community Health. 2020;45(6):1270-1282.
2. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-128.
3. Goswara G, Pin AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575-e582.
4. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):e437-e445.
5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
6. Uaprasert N, Moonla C, Sosothikul D, Rojnuckarin P, Chiasakul T. Systemic coagulopathy in hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021;27:1076029620987629. doi:10.1177/1076029620987629
7. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686.
8. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7):1178-1191.
9. Malas MB, Naaize IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. eClinicalMedicine. 2020;29:100639. doi:10.1016/j.eclinm.2020.100639
10. Tritschler T, Mathieu M-E, Skeith L, et al. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18(11):2958-2967.
11. Spyropoulos AC, Levy JH, Agno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865.
12. Moores LK, Tritschler T, Brosnanah S, et al. Prevention, diagnosis, and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest. 2020;158(3):1143-1163.
13. Schümann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225.
14. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
15. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, mortality, bleeding, and pathology among patients hospitalized with COVID-19: A single health system study. J Am Coll Cardiol. 2020;76(16):1815-1826.
16. Klok FA, Kraui MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-150.
17. Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: A pooled analysis. Thromb Haemost. 2021;121(1):76-85.
18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
19. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
20. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. 2020;383(25):2451-2460.
21. Schulman S, Kearon C. Subcommittee on control of anticoagulation and Standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.
23. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
24. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.

26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.

27. Al-Samkari H, Gupta S, Karp Leaf R, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med. 2021;M20-6739. doi:10.7326/M20-6739

28. Alonso-Fernández A, Toledo-Pons N, Cosio BG, et al. Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study. PLoS One. 2020;15(8):e0238216. doi:10.1371/journal.pone.0238216

29. Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1):211-216.

30. Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with COVID-19. J Thromb Thrombolysis. 2020;50(2):298-301.

31. Beyls C, Huette P, Abou-Arab O, Berna P, Mahjoub Y. Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis. Br J Anaesth. 2020;125(2):e260-e262.

32. Chen F, Sun W, Sun S, Li Z, Wang Z, Yu L. Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China. Clin Transl Med. 2020;10(2):e40. doi:10.1002/ctm2.40.

33. Contou D, Pajot O, Cally R, et al. Pulmonary embolism or thrombosis in ARDS COVID-19 patients: A French monocenter retrospective study. PLoS One. 2020;15(8):e0238413. doi:10.1371/journal.pone.0238413

34. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.

35. Desborough MJR, Doyle AJ, Griffiths A, Retter A, Breen KA, Hunt BJ. Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. Thorax Res. 2020;193:1-4.

36. Ferguson J, Volk S, Vondracek T, Flanigan J, Chernaik A. Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study. J Clin Pharmacol. 2020;60(11):1411-1415.

37. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res. 2020;158:104931. doi:10.1016/j.phrs.2020.104931

38. Hanif A, Khan S, Mantri N, et al. Thrombotic complications and anticoagulation in COVID-19 pneumonia: A New York City hospital experience. Ann Hematol. 2020;99(10):2323-2328.

39. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.

40. Hsu A, Liu Y, Zayac AS, Olszewski AJ, Reagan JL. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. Thromb Res. 2020;196:375-378.

41. Ibanez C, Perdomo J, Calvo A, et al. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis. 2021;51(2):308-312.

42. Ionescu F, Jaiyesimi I, Petrescu I, et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. Eur J Haematol. 2021;106(2):165-174.

43. Khalil K, Agbontaen K, McNally D, et al. Clinical characteristics and 28-day mortality of medical patients admitted with COVID-19 to a central London teaching hospital. J Infect. 2020;81(3):e85-e89. doi:10.1016/j.jinf.2020.06.027

44. Lemos ACB, do Espirito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359-366.

45. Llitjos JF, Leclere M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-1746.

46. Maatman TK, Jalali F, Feizpour C, et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48(9):e783-e790.

47. Melmed KR, Cao M, Dogra S, et al. Risk factors for intracerebral hemorrhage in patients with COVID-19. J Thromb Thrombolysis. 2020;1-8. [Epub ahead of print]. doi:10.1007/s11239-020-02288-0

48. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002.

49. Paolisso P, Bergamaschi L, D’Angelo EC, et al. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol. 2020;11:1124. doi:10.3389/fphar.2020.01124

50. Pavoni V, Giansello L, Puzzi M, Sera C, Meconi T, Frigeri FC. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Thromb Res. 2020;196:313-317.

51. Pesavento R, Ceccato D, Pasquetto G, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19: The Padua province experience. J Thromb Haemost. 2020;18(10):2629-2635.

52. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: A United States cohort study. Am J Obstet Gynecol MFM. 2020;2(3):100134. doi:10.1016/j.ajogmf.2020.100134

53. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-1751.

54. Thomas W, Varley J, Johnston A, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76-77.
55. Travi G, Rossotti R, Merli M, et al. Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience. *Am J Transplant.* 2020;20(9):2628-2629.

56. Vizcaychipi MP, Shovlin CL, McCarthy A, et al. Increase in COVID-19 inpatient survival following detection of thromboembolic and cytokine storm risk from the point of admission to hospital by a near real time traffic-light system (TraCe-Tic). *Braz J Infect Dis.* 2020;24(5):412-421.

57. Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. *J Am Coll Surg.* 2020;231(2):193-203.e1. doi:10.1016/j.jamcollsurg.2020.05.007

58. Yuriditsky E, Horowitz JM, Merchan C, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. *Crit Care Med.* 2020;48(9):1319-1326.

59. Zeng DX, Xu JL, Mao QX, et al. Association of Padua prediction score with in-hospital prognosis in COVID-19 patients. *QJM.* 2020;113(11):789-793.

60. Zerwes S, Hernandez Cancino F, et al. Increased risk of deep vein thrombosis in intensive care unit patients with COVID-19 infections?-Preliminary data. *Chirurg.* 2020;91(7):588-594.

61. Chowdhury JF, Moores LK, Connors JM. Anticoagulation in hospitalized patients with COVID-19. *N Engl J Med.* 2020;383(17):1675-1678.

62. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood.* 2020;136(4):489-500.

63. Liu J, Li J, Arnold K, Pawlinski R, Key NS. Using heparin molecules to manage COVID-19. *Res Pract Thromb Haemost.* 2020;4(4):518-523.

64. Bujsersa B, Yanginlara C, Maciej-Hulmea ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. *EBioMedicine.* 2020;59:102969. doi:10.1016/j.ebiom.2020.102969

65. Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated with venous thromboembolism: A systematic review and Bayesian meta-analysis. *Lancet Haematol.* 2020;7(8):e83-e93. doi:10.1016/S2352-3026(20)30211-8

66. Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. *JAMA.* 2020;324(13):1330-1341.

67. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. *N Engl J Med.* 2021;384(1):20-30.

68. Severino P, D’Amato A, Pucci M, et al. Ischemic heart disease pathophysiology paradigms overview: From plaque activation to microvascular dysfunction. *Int J Mol Sci.* 2020;21(21):8118. doi:10.3390/ijms21218118

69. Fedele F, Infusino F, Severino P, Mancone M. The role of cardiologists in the coronavirus disease 2019 pandemic. *Kardiol Pol.* 2020;78(7-8):808-809.

70. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. *Semin Thromb Hemost.* 2015;41(1):49-60.

71. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. *Blood.* 2005;106(8):2710-2715.

72. Daviet F, Guervilly C, Baldesi O, et al. Heparin-induced thrombocytopenia in severe COVID-19. *Circulation.* 2020;142(19):1875-1877.

73. Warrior S, Behrens E, Gezer S, Venugopal P, Jain S. Heparin induced thrombocytopenia in patients with COVID-19. *Blood.* 2020;136(Suppl1):17-18. doi:10.1182/blood-2020-134702

74. Kamel AM, Sobhy M, Magdy N, Sabry N, Farid S. Anticoagulation outcomes in hospitalized COVID-19 patients: A systematic review and meta-analysis of case-control and cohort studies. *Rev Med Virol.* 2020;e2180. doi:10.1002/rmv.2180

75. Wijaya I, Andhika R, Huang I. The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: A systematic review. *Clin Appl Thromb Hemost.* 2020;26:1076029620960797. doi:10.1177/1076029620960797

76. Grimes DA, Schulz KF. Bias and causal associations in observational research. *Lancet.* 2002;359(9302):248-252.

77. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med.* 2011;365(23):2167-2177.

78. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med.* 2013;368(6):513-523.

79. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. *N Engl J Med.* 2016;375(6):534-544.

80. Iba T, Connors JM, Spyropoulos AC, Wada H, Levy JH. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? *Int J Hematol.* 2021;113(3):330-336.